Skip to main content
Clinical Trials/NCT05204069
NCT05204069
Completed
Not Applicable

Screening for 3-D Visual Disorders in Preschool Children, VISION Study

Assistance Publique - Hôpitaux de Paris1 site in 1 country95 target enrollmentJanuary 1, 2021

Overview

Phase
Not Applicable
Intervention
Instillation of cyclopentolate
Conditions
Amblyopia
Sponsor
Assistance Publique - Hôpitaux de Paris
Enrollment
95
Locations
1
Primary Endpoint
Screening for 3-dimensional visual disorders
Status
Completed
Last Updated
4 years ago

Overview

Brief Summary

Visual screening is necessary among pre-school children as they found themselves in a critical period of visual developement. To date, there are no national vision screening program that has been implemented nationwide. Vision is a pilot feasibility multicentric cluster study comparing the sensitivity of "AFSOP 3 dimensional visual screening protocol in a population of 3 to 4-year-old pre-school children conducted in 4 kindergarten preschools in Paris with gold-standard ophthalmic examination confirmation.

Detailed Description

Visual screening is necessary among pre-school children as they found themselves in a critical period of visual developement. To date, there are no national vision screening program that has been implemented nationwide. Methodology: The "Association Française de Strabologie et d'Ophtalmologie Pédiatrique" AFSOP proposed criteria based on a 3-dimensions visual screening to assess whether or not a child presents risk factors of amblyopia such as ametropia, strabismus and anisometropia. Vision is a pilot feasibility multicentric cluster study comparing the sensitivity of "AFSOP 3 dimensional visual screening protocol in a population of 3 to 4-year-old pre-school children conducted in 4 kindergarten preschools in Paris with gold-standard ophthalmic examination confirmation. Expected results: We assume that a vision screening operated with the AFSOP 3 dimension screening recommendations and conducted by paramedical actors such as orthoptists will prove more sensitive and easier to implement on a national scale.

Registry
clinicaltrials.gov
Start Date
January 1, 2021
End Date
September 1, 2021
Last Updated
4 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Children aged 3 to 4 years
  • Enrolled in kindergarten in the first section
  • In the 19th district of Paris
  • Who should benefit from visual screening via the school medical service

Exclusion Criteria

  • Children who do not speak French
  • Children who are physically or cognitively unable to participate in the screening

Arms & Interventions

Three-dimensional screening for visual disorders using the RetinoMax Device

Instillation of cyclopentolate of 3 drops of cyclopentolate at T0',T5' and t10' with to induce a certain level of cycloplegia and evaluate manifest refraction at t45' using the RetinoMax Device.

Intervention: Instillation of cyclopentolate

Non-standardized device for usual vision disorders

Screening device for usual vision disorders, performed by the school doctor during the usual prevention visit, with the tools used in the school doctor's current practice, non-standardized, according to his preference

Intervention: Instillation of cyclopentolate

Outcomes

Primary Outcomes

Screening for 3-dimensional visual disorders

Time Frame: 1 day

Sensitivity of the " AFSOP 3-dimensional screening" vs "PARIS protocol screening" using a comprehensive ophthalmological examination as a gold standard

Study Sites (1)

Loading locations...

Similar Trials